Bal Pharma Ltd vs Piramal Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bal Pharma Ltd is ₹ 75.09 as of 05 May 15:30 . The P/E Ratio of Bal Pharma Ltd changed from 16.8 on March 2021 to 18.4 on March 2025 . This represents a CAGR of 1.84% over 5 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 years The Market Cap of Bal Pharma Ltd changed from ₹ 79.67 crore on March 2021 to ₹ 132.4 crore on March 2025 . This represents a CAGR of 10.69% over 5 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 years The revenue of Bal Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 88.02 crore. This represent the decline of -100% The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The ebitda of Bal Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 9.87 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The net profit of Bal Pharma Ltd changed from ₹ 0.26 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The Dividend Payout of Bal Pharma Ltd changed from 16.29 % on March 2021 to 24.49 % on March 2025 . This represents a CAGR of 8.50% over 5 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 years .

About Bal Pharma Ltd

Bal Pharma Limited (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 1987.
In March 1990, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc.
The company promotes its products through the common sales force of the group but proposes to induct its own soon.
It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

FAQs for the comparison of Bal Pharma Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Bal Pharma Ltd or Piramal Pharma Ltd?

Market cap of Bal Pharma Ltd is 119 Cr while Market cap of Piramal Pharma Ltd is 21,241 Cr

What are the key factors driving the stock performance of Bal Pharma Ltd and Piramal Pharma Ltd?

The stock performance of Bal Pharma Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bal Pharma Ltd and Piramal Pharma Ltd?

As of May 5, 2026, the Bal Pharma Ltd stock price is INR ₹75.09. On the other hand, Piramal Pharma Ltd stock price is INR ₹159.8.

How do dividend payouts of Bal Pharma Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Bal Pharma Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.